Black Diamond Therapeutics Inc
BDTX2.255USD
+0.095+4.40%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
128.41MCap. mercado
5.95P/E TTM
Más Datos de Black Diamond Therapeutics Inc Compañía
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Información de Black Diamond Therapeutics Inc
Símbolo de cotizaciónBDTX
Nombre de la empresaBlack Diamond Therapeutics Inc
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoVelleca (Mark A)
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección245 First Street, 18Th Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16174175868
Sitio Webhttps://www.blackdiamondtherapeutics.com/
Símbolo de cotizaciónBDTX
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoVelleca (Mark A)
Ejecutivos de Black Diamond Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
86.65K
+5208.00%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
+85150.00%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-20.00%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
31.03K
+4665.00%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
86.65K
+5208.00%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
+85150.00%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-20.00%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
31.03K
+4665.00%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Otro
48.86%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Otro
48.86%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
30.59%
Investment Advisor/Hedge Fund
20.77%
Venture Capital
19.08%
Hedge Fund
7.72%
Research Firm
1.42%
Individual Investor
0.92%
Pension Fund
0.02%
Otro
19.48%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
251
45.27M
104.04%
+4.70K
2025Q3
261
45.26M
106.75%
+270.69K
2025Q2
263
45.72M
119.11%
-2.33M
2025Q1
244
48.05M
134.35%
-28.07M
2024Q4
236
55.25M
127.86%
-855.91K
2024Q3
237
56.09M
121.86%
+1.99M
2024Q2
230
54.06M
101.77%
+8.09M
2024Q1
233
46.69M
117.14%
-13.89M
2023Q4
222
46.16M
104.70%
+1.30M
2023Q3
240
44.37M
104.97%
-4.12M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
10.74M
18.86%
+231.97K
+2.21%
Sep 30, 2025
Versant Ventures
6.21M
10.89%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.55M
9.74%
-50.00K
-0.89%
Sep 30, 2025
New Enterprise Associates (NEA)
4.45M
7.81%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.19M
3.84%
+85.83K
+4.08%
Sep 30, 2025
Tang Capital Management, LLC
2.07M
3.63%
--
--
Sep 30, 2025
Marshall Wace LLP
1.30M
2.28%
+561.33K
+76.07%
Sep 30, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
896.85K
1.57%
+758.71K
+549.22%
Sep 30, 2025
Millennium Management LLC
850.33K
1.49%
-94.52K
-10.00%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Fidelity Enhanced Small Cap ETF
0.05%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
DFA Dimensional US Small Cap Value ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Health Innovation Active ETF
0%
Vanguard US Momentum Factor ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver más
Fidelity Enhanced Small Cap ETF
Proporción0.05%
iShares Micro-Cap ETF
Proporción0.03%
Avantis US Small Cap Equity ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
DFA Dimensional US Small Cap Value ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
iShares Health Innovation Active ETF
Proporción0%
Vanguard US Momentum Factor ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
